WATERLOO, ONT., May 4, 2021 – Curiato Inc. today announced a CEO transition with the appointment of Dr. Thomas P. Stewart to the role of Interim CEO. The expansion of the leadership team will enable Curiato to accelerate its commercialization timeline and scale-up.
Dr. Stewart is an industry veteran who is the founder of the National Pressure Injury Advisory Panel (NPIAP) and has served in various senior leadership roles with Gaymar Industries, Stryker, Milsport Medical, and Board positions with the Roswell Park Cancer Institute and the Buffalo Niagara Partnership.
“I am thrilled to be joining as Interim CEO,” said Dr. Stewart. “The progress made under the founding team has been tremendous. I am honoured in the trust placed in me to continue this tradition and also for the opportunity to lead our team on the next leg of what promises to be an exciting journey. Having served as an advisor to the company for the past 2 years, I strongly believe in the potential of patient data and insights - derived from the surface of the bed - to tackle some of health care’s most significant and costliest challenges.”
Along with the CEO transition, the company is also expanding its leadership team with the addition of Jim Price as VP Product and Dr. Cynthia Sylvia as VP Clinical Affairs. Jim is an experienced product development and marketing executive who had previous product leadership roles with Hillrom, Gaymar Industries, Extremiti 3D, and Tridien Medical. Dr. Sylvia is an experienced clinical leader with deep expertise in the nursing and wound care space with industry experience through roles with Stryker and Gaymar Industries. Collectively, the new leadership team appointments have the industry credibility and experience to transition Curiato from a validated startup to be recognized as a market player with its first use case of providing clinical decision support to improve pressure injury prevention practices.
“Curiato had a successful year in 2020 during which our company achieved its major milestones – positive clinical validation, Health Canada licensing, FDA registration, and our first commercial deployment,” said Moazam Khan, Co-founder. “With emphasis shifting to scale-up as well as clinical and commercial execution going forward, these
leadership changes best position us for future success. Please join me in extending a warm welcome to Tom, Jim, and Cindy.”
The Board of Directors, with guidance from our shareholders and support from Dr. Stewart, will lead the search for a permanent CEO. “The co-founders remain active on the Board of Directors and continue to serve within Curiato. These changes are a testament to their entrepreneurialism and pragmatism,” adds Dr. Stewart.
Investor Relations Contact
Dean Sas, CBO/CFO
dsas@curiato.com
Media Relations Contact
John Gregory
jgregory@curiato.com
About Curiato
Curiato, Inc. is a commercial-stage digital health company and leader in the new category of smart surface monitoring. Our lead product offering – PI CONNECTTM – delivers actionable patient insights from the bed surface which can be used for clinical decision support. Our platform combines a smart bed cover - which converts any medical mattress into a smart bed - and predictive analytics to harness a new category of quality, objective patient data & insights. Through our clinical research to date we have evidence validating four patient insights – mobility, moisture, temperature, and posture. Our lead offering for pressure injuries is in-market and registered for sale with Health Canada & FDA. Our long-term strategy is to use our patient insights to create an ecosystem of clinical decision support apps for pressure injuries, infectious disease, cardiology, burns, robotic surgery, and more.
About Dr. Thomas P. Stewart
https://www.linkedin.com/in/dr-thomas-stewart-5337699/
Safe Harbour Statement
This press release contains "forward-looking information" within the meaning of applicable securities legislation. All information contained herein that is not clearly historical in nature may constitute forward- looking information. Generally, such forward looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes”, or variations thereof or statements that certain actions, events or results “may”, “could”, “would”, “might” occur. Without limiting the generality of the foregoing, the business model and go-to-market strategy sections of this presentation constitute forward-looking information. Although Curiato, Inc. (the “Company”) has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results to differ from what the Company anticipated, estimated or intended, including without limitation: (i) the general global markets and economic conditions; (ii) the possibility that our business model may not gain market acceptance if at all; (iii) competition faced by the Company in securing experienced personnel and financing; (iv) risks related to regulatory issues; (v) risks related to potential conflicts of interest; (vi) the reliance on key personnel; (vii) the proposed investment will not enable us to reach the milestones; (viii) the risk of intellectual property litigation; (ix) risk management and (x) other circumstances beyond the Company’s control. Such forward-looking information has been provided for the purpose of assisting investors in understanding the Company’s business and operations and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is made as of the date of this presentation. The Company neither makes any representations or warranties as to the accuracy of forward-looking information nor undertakes to update such forward looking information except in accordance with applicable securities legislation.
